Cancer Stem Cells in Human Prostate Cancer. Role in Drug Resistance and Metastasis
Contenido principal del artículo
Resumen
Prostate cancer is one of the most important causes of oncologic death in men, and Chile has also reached that level. Prostate cancer mortality is mostly associated with metastatic disease where the cancer is usually resistant to available treatments, particularly hormone- therapy and chemotherapy. It has been suggested that the existence of cancer stem cells could account for the metastatic capacity and treatment resistance in most cancers. Recently, cells with stem characteristics have been identified in established cell lines and animal models of prostate cancer. We have isolated and characterized this kind of cells from patient tumors. This finding opens the possibility to manipulate them as potential therapeutic targets.
Citas
Acloque, H.; Adams, M. S.; Fishwick, K.; BronnerFraser, M. & Nieto, M. A. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J. Clin. Invest., 119(6):1438-49 2009.
Alberts, S. R. & Wagman, L. D. Chemotherapy for colorectal cancer liver metastases. Oncologist, 13(10):1063-73, 2008.
Altaner, C. Prodrug cancer gene therapy. Cancer Lett., 270(2):191-201, 2008.
Berry, P. A.; Maitland, N. J. & Collins, A. T. Androgen receptor signalling in prostate: effects of stromal factors on normal and cancer stem cells. Mol. Cell. Endocrinol., 288(1-2):30-7, 2008.
Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med., 3(7):730-7, 1997.
Borst, P.; Jonkers, J.& Rottenberg, S. What makes tumors multidrug resistant? Cell Cycle, 6(22):2782-7, 2007.
Cabanillas, R. & Llorente, J. L. The Stem Cell Network model: clinical implications in cancer. Eur. Arch. Otorhinolaryngol., 266(2):161-70, 2009.
Castellón, E.; Clementi, M.; Hitschfeld, C.; S·nchez, C.; Benítez, D.; Sáenz, L.; Contreras, H. & Huidobro, C. Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest., 24(3):261- 2006.
Castellón, E.; Venegas, K.; S·enz, L.; Contreras, H. & Huidobro, C. Secretion of prostatic specific antigen, proliferative activity and androgen response in epithelial-stromal co-cultures from human prostate carcinoma. Int. J. Androl., 28(1):39-46, 2005.
Celia-Terrassa, T.; Meca-Cortés, O.; Mateo, F.; de Paz, A. M.; Rubio, N.; Arnal-Estapé, A.; Ell, B. J.; Bermudo, R.; Díaz, A.; Guerra-Rebollo, M.; Lozano, J. J.; Estar·s, C.; Ulloa, C.; ¡lvarez-Simún, D.; Mila, J.; Vilella, R.; Paciucci, R.; MartínezBalb·s,M.; de Herreros, A. G.; Gomis, R. R.; Kang, Y.; Blanco, J.; Fernández, P. L. & Thomson, T. M. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumorinitiating cells. J. Clin. Invest., 122(5):1849-68,2012.
Chiang, A. C. & Massagué, J. Molecular basis of metastasis. N. Engl. J. Med., 359(26):2814-23, 2008.
Cifuentes, F. F.; Valenzuela, R. H.; Contreras, H. R. & CastellÛn, E. A. Development of an orthotopic model of human metastatic prostate cancer in the NOD-SCIDY mouse (Mus musculus) anterior prostate. Oncol. Lett., 10(4):2142-8, 2015a.
Cifuentes, F. F.; Valenzuela, R. H.; Contreras, H. R. & Castellón, E. A. Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer. Oncol. Rep., Oct 1. doi: 10.3892/or.2015.4319. 2015b. [Epubahead of print]
Clementi, M.; Sánchez, C.; Benitez, D. A.; Contreras, H. R.; Huidobro, C.; Cabezas, J.; Acevedo, C. & Castellón, E. A. Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas. Prostate, 69(10):1025-33, 2009.
Contreras, H. R.; Ledezma, R. A.; Vergara, J.; Cifuentes, F.; Barra, C.; Cabello, P.; Gallegos, I.; Morales, B.; Huidobro, C. & Castellon, E. A. The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, Ecadherin and beta-catenin, in prostate cancer. Urol. Oncol., 28(5):534-40, 2010.
de Silva Rudland, S.; Platt-Higgins, A.; Winstanley, J. H.; Jones, N. J.; Barraclough, R.; West, C.; Carroll, J. & Rudland, P. S. Statistical association of basal cell keratins with metastasis-inducing proteins in a prognostically unfavorable group of sporadic breast cancers. Am. J. Pathol., 179(2):1061-72, 2011.
Di Zazzo, E.; Galasso, G.; Giovannelli, P.; Di Donato, M.; Di Santi A, Cernera, G.; Rossi, V.; Abbondanza, C.; Moncharmont, B.; Sinisi, A. A.; Castoria, G. & Migliaccio, A. Prostate cancer stem cells: the role of androgen and estrogen receptors. Oncotarget, doi: 10.18632/oncotarget.6220, 2015. [Epub ahead of print]
Drewa, T. & Styczynski, J. Can conception of prostate cancer stem cells influence treatment dedicated to patients with disseminated disease? Med. Hypotheses, 71(5):694-9, 2008.
Filip, S.; Mokry, J.; Horacek, J. & English, D. Stem cells and the phenomena of plasticity and diversity: a limiting property of carcinogenesis. Stem Cells Dev., 17(6):1031-8, 2008.
Finch, A. R.; Sedgley, K. R.; Caunt, C. J. & McArdle, C. A. Plasma membrane expression of GnRH receptors: regulation by antagonists in breast, prostate, and gonadotrope cell lines. J. Endocrinol., 196(2):353-67, 2008.
Fioriti, D.; Mischitelli, M.; Di Monaco, F.; Di Silverio, F.; Petrangeli, E.; Russo, G.; Giordano, A. & Pietropaolo, V. Cancer stem cells in prostate adenocarcinoma: a target for new anticancer strategies. J. Cell. Physiol., 216(3):571-5, 2008.
Gao, J. X. Cancer stem cells: the lessons from precancerous stem cells. J. Cell. Mol. Med., 12(1):67- 96, 2008.
Garraway, I. P.; Sun, W.; Tran, C. P.; Perner, S.; Zhang, B.; Goldstein, A. S.; Hahm, S. A.; Haider, M.; Head, C. S.; Reiter, R. E.; Rubin, M. A. & Witte, O. N. Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate, 70(5):491-501, 2010.
Gil, J.; Stembalska, A.; Pesz, K. A. & Sasiadek, M. M. Cancer stem cells: the theory and perspectives in cancer therapy. J. App. Genet., 49(2):193-9, 2008.
Glinsky, G. V. "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J. Clin. Oncol., 26(17):2846-53, 2008.
Gnanapragasam, V. J.; Darby, S.; Khan, M. M.; Lock, W. G.; Robson, C. N. & Leung, H. Y. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer. J. Pathol., 206(2):205-13, 2005.
International Agency for Research of Cancer. Globocan. Geneve, World Health Organization, 2012. Disponible en: http://globocan.iarc.fr/ Pages/fact_sheets_cancer.aspx
Hollier, B. G.; Evans, K. & Mani, S. A. The epithelialto-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J. Mammary Gland. Biol. Neoplasia, 14(1):29-43, 2009.
Isaacs, J. T. Prostate stem cells and benign prostatic hyperplasia. Prostate, 68(9):1025-34, 2008.
Ishii, H.; Iwatsuki, M.; Ieta, K.; Ohta, D.; Haraguchi, N.; Mimori, K. & Mori, M. Cancer stem cells and chemoradiation resistance. Cancer Sci., 99(10):1871-7, 2008.
Janovick, J. A.; Patny, A.; Mosley, R.; Goulet, M. T.; Altman, M. D.; Rush, T. S. 3rd.; Cornea, A. & Conn, P. M. Molecular mechanism o f action o f pharmacoperone rescue of misrouted GPCR mutants: the GnRH receptor. Mol. Endocrinol., 23(2):157-68, 2009.
Janovick, J. A.; Ulloa-Aguirre, A. & Conn, P. M. Evolved regulation of gonadotropin-releasing hormone receptor cell surface expression. Endocrine, 22(3):317-27, 2003.
Kaplan, R. N.; Psaila, B. & Lyden, D. Bone marrow cells in the 'pre-metastatic niche': within bone and beyond. Cancer Metastasis Rev., 25(4):521-9, 2006.
Kasper, S. Stem cells: The root of prostate cancer? J. Cell. Physiol., 216(2):332-6, 2008.
Kelly, K. & Yin, J. J. Prostate cancer and metastasis initiating stem cells. Cell Res., 18(5):528-37, 2008.
Kollmeier, M. A. & Zelefsky, M. J. What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer? Nat. Clin. Pract. Urol., 5(11):584-5, 2008.
Kotb, A. F. & Elabbady, A. A. Prognostic factors for the development of biochemical recurrence after radical prostatectomy. Prostate Cancer, 2011:485189, 2011.
Kurokawa, Y. & Sasako, M. Recent advances in chemotherapy and chemoradiotherapy for gastrointestinal tract cancers: adjuvant chemoradiotherapy for gastric cancer. Int. J. Clin. Oncol., 13(6):479-82, 2008.
Lang, S. H.; Frame, F. M. & Collins, A. T. Prostate cancer stem cells. J. Pathol., 217(2):299-306, 2009.
Lapidot, T.; Sirard, C.; Vormoor, J.; Murdoch, B.; Hoang, T.; Caceres-Cortes, J.; Minden, M.; Paterson, B.; Caligiuri, M. A. & Dick, J. E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367(6464):645-8, 1994.
Le Tourneau, C.; Faivre, S. & Raymond, E. New developments in multitargeted therapy for patients with solid tumours. Cancer Treat. Rev., 34(1):37-48, 2008.
Leaños-Miranda, A.; Ulloa-Aguirre, A.; Janovick, J. A. & Conn, P. M. In vitro coexpression and pharmacological rescue of mutant gonadotropinreleasing hormone receptors causing hypogonadotropic hypogonadism in humans expressing compound heterozygous alleles. J. Clin. Endocrinol. Metab., 90(5):3001-8, 2005.
Lee, E. C. & Tenniswood, M. P. Emergence of metastatic hormone-refractory disease in prostate cancer after anti-androgen therapy. J. Cell. Biochem., 91(4):662-70, 2004.
Leong, K. G.; Wang, B. E.; Johnson, L. & Gao, W. Q. Generation of a prostate from a single adult stem cell. Nature, 456(7223):804-8, 2008.
Lewis, M. T. Faith, heresy and the cancer stem cell hypothesis. Future Oncol., 4(5):585-9, 2008.
Lichtenauer, U. D. & Beuschlein, F. The tumor stem cell concept-implications for endocrine tumors? Mol. Cell. Endocrinol., 300(1-2):158-63, 2009.
Lobo, N. A.; Shimono, Y.; Qian, D. & Clarke, M. F. The biology of cancer stem cells. Annu. Rev. Cell Dev. Biol., 23:675-99, 2007.
Lowrance, W. T.; Roth, B. J.; Kirkby, E.; Murad, M. H. & Cookson, M. S. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2015. J. Urol., pii:S0022-5347(15)05026-0, 2015.
Maitland, N. J. & Collins, A. T. Prostate cancer stem cells: a new target for therapy. J. Clin. Oncol., 26(17):2862-70, 2008.
Masters, J. R.; Kane, C.; Yamamoto, H. & Ahmed, A. Prostate cancer stem cell therapy: hype or hope? Prostate Cancer Prostatic Dis., 11(4):316-9, 2008.
Mathew, G.; Timm, E. A. Jr.; Sotomayor, P.; Godoy, A.; Montecinos, V. P.; Smith, G. J. & Huss, W. J. ABCG2-mediated DyeCycle Violet efflux defined side population in benign and malignant prostate. Cell Cycle, 8(7):1053-61, 2009.
McPhaul, M. J. Mechanisms of prostate cancer progression to androgen independence. Best Pract. Res. Clin. Endocrinol. Metab., 22(2):373- 88, 2008.
Merseburger, A. S.; Belka, C.; Behmenburg, K. & Stenzl, A. Secondary hormonal manipulation. Front. Radiat. Ther. Oncol., 41:93-102, 2008.
Michael, A.; Syrigos, K. & Pandha, H. Prostate cancer chemotherapy in the era of targeted therapy. Prostate Cancer Prostatic Dis., 12(1):13-6, 2009.
Miki, J. & Rhim, J. S. Prostate cell cultures as in vitro models for the study of normal stem cells and cancer stem cells. Prostate Cancer Prostatic Dis., 11(1):32-9, 2008.
Miki, J. Investigations of prostate epithelial stem cells and prostate cancer stem cells. Int. J. Urol., 17(2):139-47, 2010.
Departamento de Estadísticas e Información de Salud (DEIS). Mortalidad. Santiago de Chile, Ministerio de Salud (MINSAL), Departamento de Estadísticas e Información de Salud (DEIS), 2015. Disponible en: http://www.deis.cl/ ?p=51
Montagnani Marelli, M.; Moretti, R. M.; Mai, S.; Januszkiewicz-Caulier, J.; Motta, M. & Limonta, P. Type I gonadotropin-releasing hormone receptor mediates the antiproliferative effects of GnRH-II on prostate cancer cells. J. Clin. Endocrinol. Metab., 94(5):1761-7, 2009.
Nelson, W. G.; De Marzo, A. M. & Isaacs, W. B. Prostate cancer. N. Engl. J. Med., 349(4):366-81, 2003.
Pardal, R.; Clarke, M. F. & Morrison, S. J. Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer, 3(12):895-902, 2003.
Pascal, L. E.; Oudes, A. J.; Petersen, T. W.; Goo, Y. A.; Walashek, L. S.; True, L. D. & Liu, A. Y. Molecular and cellular characterization of ABCG2 in the prostate. B. M. C. Urol., 7:6, 2007.
Patrawala, L.; Calhoun, T.; Schneider-Broussard, R.; Li, H.; Bhatia, B.; Tang, S.; Reilly, J. G.; Chandra, D.; Zhou, J.; Claypool, K.; Coghlan, L. & Tang, D. G. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene, 25(12):1696-708, 2006.
Patrawala, L.; Calhoun, T.; Schneider-Broussard, R.; Zhou, J.; Claypool, K. & Tang, D. G. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res., 65(14):6207-19, 2005.
Patrawala, L.; Calhoun-Davis, T.; SchneiderBroussard, R. & Tang, D. G. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res., 67(14):6796-805, 2007.
Poblete, C. E.; Fulla, J.; Gallardo, M.; Muñoz, V.; CastellÛn, E. A.; Gallegos, I. & Contreras, H. R. Increased SNAIL expression and low syndecan levels are associated with high Gleason grade in prostate cancer. Int. J. Oncol., 44(3):647-54, 2014.
Reya, T.; Morrison, S. J.; Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature, 414(6859):105-11, 2001.
Risinger, A. L.; Giles, F. J. & Mooberry, S. L. Microtubule dynamics as a target in oncology. Cancer Treat. Rev., 35(3):255-61, 2009.
Roussel, B.; Ouellet, G. M.; Mohile, S. G. & Dale, W. Prostate Cancer in Elderly Men: Screening, Active Surveillance, and Definitive Therapy. Clin. Geriatr. Med., 31(4):615-29, 2015.
Sánchez, C.; Mercado, A.; Contreras, H. R.; Mendoza, P.; Cabezas, J.; Acevedo, C.; Huidobro, C. & Castellón, E. A. Chemotherapy sensitivity recovery of prostate cancer cells by functional inhibition and knock down of multidrug resistance proteins. Prostate, 71(16):1810-7, 2011.
Sánchez, C.; Clementi, M.; Benitez, D.; Contreras, H.; Huidobro, C. & Castelon, E. Effect of GnRH analogs on the expression of TrkA and p75 neurotrophin receptors in primary cell cultures from human prostate adenocarcinoma. Prostate, 65(3):195-202, 2005.
Sánchez, C.; Mendoza, P.; Contreras, H. R.; Vergara, J.; McCubrey, J. A.; Huidobro, C. & Castellon, E. A. Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. Prostate, 69(13):1448- 59, 2009.
Shah, R. B.; Mehra, R.; Chinnaiyan, A. M.; Shen, R.; Ghosh, D.; Zhou, M.; Macvicar, G. R.; Varambally, S.; Harwood, J.; Bismar, T. A.; Kim, R.; Rubin, M. A. & Pienta, K. J. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res., 64(24):9209-16, 2004.
Sharifi, N.; Hurt, E. M. & Farrar, W. L. Androgen receptor expression in prostate cancer stem cells: is there a conundrum? Cancer Chemother. Pharmacol., 62(5):921-3, 2008.
Sharom, F. J. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics, 9(1):105-27, 2008.
Sherman, S. I. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J. Clin. Endocrinol. Metab., 94(5):1493- 9, 2009.
Shipitsin, M. & Polyak, K. The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab. Invest., 88(5):459-63, 2008.
Stavrovskaya, A. A. & Stromskaya, T. P. Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry (Mosc.), 73(5):592-604, 2008.
Sundaram, S.; Durairaj, C.; Kadam, R. & Kompella, U. B. Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. Mol. Cancer Ther., 8(6):1655-65, 2009.
Sutton, L. M.; Han, J. S.; Molberg, K. H.; Sarode, V. R.; Cao, D.; Rakheja, D.; Sailors, J. & Peng, Y. Intratumoral expression level of epidermal growth factor receptor and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma. Am. J. Clin. Pathol., 134(5):782-87,2010.
Suzuki, H.; Kamiya, N.; Imamoto, T.; Kawamura, K.; Yano, M.; Takano, M.; Utsumi, T.; Naya, Y. & Ichikawa, T. Current topics and perspectives relating to hormone therapy for prostate cancer. Int. J. Clin. Oncol., 13(5):401-10, 2008.
Szabó, J.; Bartók, K.; Krencs, T.; Szepesvry, Z. & Szende, B. GnRH receptor and androgen receptor status and outcome of advanced prostate carcinomas. Anticancer Res., 29(2):681-4, 2009.
Takao, T. & Tsujimura, A. Prostate stem cells: the niche and cell markers. Int. J. Urol., 15(4):289- 94, 2008.
Tang, D. G.; Patrawala, L.; Calhoun, T.; Bhatia, B.; Choy, G.; Schneider-Broussard, R. & Jeter, C. Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol. Carcinog., 46(1):1-14, 2007.
Timms, B. G. Prostate development: a historical perspective. Differentiation, 76(6):565-77, 2008.
Vaishampayan, U. N.; Marur, S.; Heilbrun, L.K.; Cher, M. L.; Dickow, B.; Smith, D. W.; Al Hasan, S. A.; Eliason, J. & Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer. J. Urol., 182(1):317-23, 2009.
van Brussel, J. P. & Mickisch, G. H. Multidrug resistance in prostate cancer. Onkologie, 26(2):175-81, 2003.
Van Poppel, H.; Joniau, S.; Van Cleynenbreugel, B.; Mottaghy, F. M. & Oyen, R. Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy. Prostate Cancer Prostatic Dis., 12(2):116-23, 2009.
Ward, R. J. & Dirks, P. B. Cancer stem cells: at the headwaters of tumor development. Annu. Rev. Pathol., 2:175-89, 2007.
Wels, J.; Kaplan, R. N.; Rafii, S. & Lyden, D. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev., 22(5):559-74, 2008.
Witz, I. P. Tumor-microenvironment interactions: dangerous liaisons. Adv. Cancer Res., 100:203- 29, 2008.
Yamashiro, H. & Toi, M. Update of evidence in chemotherapy for breast cancer. Int. J. Clin. Oncol., 13(1):3-7, 2008.
Zhou, S.; Schuetz, J. D.; Bunting, K. D.; Colapietro, A. M.; Sampath, J.; Morris, J. J.; Lagutina, I.; Grosveld, G. C.; Osawa, M.; Nakauchi, H. & Sorrentino, B. P. The ABC transporter Bcrp1/ ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the sidepopulation phenotype. Nat. Med., 7(9):1028-34, 2001.